Epigral Reports Decline in Financial Performance for Q4 2023

Epigral, a smallcap chemical company, recently announced its financial results for the quarter ending December 2023. The company's stock has been given a 'Sell' call by MarketsMOJO.

According to the financial report, Epigral has seen a negative performance in the quarter, with a score of -11, which has improved from -15 in the last three months. This indicates a decline in the company's financial health.

One of the major factors contributing to this decline is the Profit Before Tax (PBT) less Other Income, which has fallen by -10.9% to Rs 71.48 crore compared to the average PBT of the previous four quarters, which was Rs 80.26 crore. This shows a negative trend in the near term for PBT.

Similarly, the Profit After Tax (PAT) has also seen a decline of -12.1% to Rs 49.08 crore compared to the average PAT of the previous four quarters, which was Rs 55.86 crore. This indicates a negative trend in the near term for PAT.

The Net Sales for the quarter have also fallen by -7.2% to Rs 471.52 crore compared to the average Net Sales of the previous four quarters, which was Rs 508.27 crore. This shows a negative trend in the near term for sales.

Overall, the financial results for the quarter ending December 2023 have not been favorable for Epigral. The company will need to address these issues and work towards improving its financial performance in the future.